Target engagement/chemoproteomics contract
Proteome Sciences plc has announced a significant new clinical contract related to its target engagement/chemoproteomics platform, which is anticipated to precede a new clinical trial program commencing later in 2026. The company highlighted continued momentum and growth in its chemoproteomics services, with the Executive Chairman expressing delight at the new contract and the considerable interest generated at the recent American Society for Mass Spectrometry meeting.
Select text to share a quote on X · sign in to keep highlights & notes in your PRM notes
Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform. The Company anticipates this contract being a precursor to a new clinical trial programme that will be initiated later in 2026.
Christopher Pearce, Executive Chairman, commented:
"We are delighted that the momentum and growth from our chemoproteomics services is continuing in the current year, as highlighted by this new contract. The Company also generated considerable interest and attention at the recent American Society for Mass Spectrometry (ASMS) meeting in San Diego, USA earlier in June and we look forward to providing shareholders with further updates regarding our chemoproteomics workstreams in due course".
Proteome Sciences plc
| Christopher Pearce, Executive Chairman | Tel: +44 (0) 20 7043 2116 |
| Richard Dennis, Chief Commercial Officer | |
| SP Angel Corporate Finance LLP (Nominated Adviser & Broker) | |
| David Hignell/Matthew Johnson/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking) | Tel: +44 (0) 20 3470 0470 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.